Outcomes of Focal Ablation for Prostate Cancer

NCT05478694 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2026-04-17

No results posted yet for this study

Summary

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Conditions

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Daniel Segal, M.D. · University of Texas Southwestern Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478694 on ClinicalTrials.gov